[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subclinical-hypothyroidism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subclinical-hypothyroidism":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,72,113,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100623171","levothyroxine-treatment-on-cardiac-function-in-children-with-subclinical-hypothyroidism-100623171",false,"NCT07393165","Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism","The Effect of Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism","Inclusion Criteria:\n\n* Age from 4 to 15 years.\n* Both sexes.\n* Patients with stable elevated thyroid-stimulating hormone (TSH) ≥ 4.5 mIU\u002FL with normal free T4 and ft3 in different measurement 4 - 6 weeks apart.\n\nExclusion Criteria:\n\n* Overweight and obesity\n* Hypertension\n* Previous use of levothyroxine, antiepileptic drugs, or cardiac drugs within the last 6 months.\n* Arrhythmia.\n* Congenital or acquired heart disease\n* Liver or kidney disease\n* Hyperlipidemia\n* Diabetes\n* Infectious diseases\n* Respiratory diseases\n* Malignancies","ALL","4 Years","15 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate the effect of the treatment with levothyroxine on cardiac function in children with subclinical hypothyroidism.",[27,28,29,30],"Levothyroxine","Cardiac Function","Children","Subclinical Hypothyroidism","RECRUITING","2026-01-31",{"date":34,"type":35},"2026-02-06","ACTUAL",{"date":37,"type":35},"2025-05-24",{"date":39,"type":21},"2026-05-01",{"name":41,"class":42},"Tanta University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100622225","thyroid-hormone-replacement-after-coronary-artery-bypass-grafting-for-patients-with-subclinical-hypothyroidism-100622225","NCT07380854","Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism","RepleniSH","Eligibility Criteria\n\n* Adults aged 19 to 90 years.\n* Patients scheduled to undergo coronary artery bypass graft (CABG) surgery.\n* Subclinical hypothyroidism (SCH), defined as a normal free thyroxine (free T4) level and a thyroid-stimulating hormone (TSH) level greater than 4 μIU\u002FmL, based on testing performed within 31 days prior to surgery.\n\nExclusion Criteria:\n\n* Patients who underwent repeat or emergency CABG surgery\n* Use of LT4 within the previous 4 weeks\n* Use of antithyroid drug use (propylthiouracil, methimazole, or carbimazole) within the previous 3 months\n* Severe comorbid conditions with a life expectancy of less than 1 year (e.g. advanced malignancy)","19 Years","90 Years",{"count":54,"type":21},338,[24],"The goal of this clinical trial is to find out whether levothyroxine reduces complications and improves the prognosis of patients with subclinical hypothyroidism (SCH) undergoing coronary artery bypass grafting (CABG).\n\nThe main questions this study aims to answer are:\n\n• Does levothyroxine reduce major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and new arrhythmias, in SCH patients undergoing CABG? Researchers will compare patients who take levothyroxine with those who do not.\n\nParticipants will:\n\n* Be randomly assigned to either receive levothyroxine or not\n* Start the medication one day before surgery if assigned to the treatment group.\n* Have regular follow-up visits to check thyroid function and cardiovascular events for up to five years after surgery.",[30],[59,60,61,62],"subclinical hypothyroidism","coronary artery bypass grafting","thyroid hormones","levothyroxine","2026-01-24",{"date":65,"type":35},"2026-02-02",{"date":67,"type":35},"2022-02-27",{"date":69,"type":21},"2037-02-26",{"name":71,"class":42},"Seoul National University Bundang Hospital",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":93,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100612720","levothyroxine-treatment-and-ivf-outcomes-in-women-with-subclinical-hypothyroidism-a-target-trial-emulation-100612720","NCT07257250","Levothyroxine Treatment and IVF Outcomes in Women With Subclinical Hypothyroidism: A Target Trial Emulation","Effectiveness of Levothyroxine Treatment on In Vitro Fertilization and Pregnancy Outcome in Women With Subclinical Hypothyroidism and Infertility: A Target Trial Emulation","LESI","Inclusion Criteria:\n\n* Women aged 18-45 years.\n* Diagnosed with subclinical hypothyroidism (TSH 4.2-\\\u003C10 mIU\u002FL with FT4 0.92-1.68 ng\u002FdL).\n* Undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) followed by frozen embryo transfer (FET).\n\nExclusion Criteria:\n\n* Overt hypothyroidism (TSH ≥10 mIU\u002FL and FT4 ≤0.92 ng\u002FdL).\n* Current or recent (within 1 month) use of drugs affecting thyroid function (levothyroxine, amiodarone, methimazole, propylthiouracil).","FEMALE","18 Years","45 Years",{"count":84,"type":21},900,"OBSERVATIONAL","Subclinical hypothyroidism (SCH) is defined by elevated thyroid-stimulating hormone (TSH) with normal free thyroxine (fT4) levels. It affects approximately 5-7% of women of reproductive age and may negatively influence outcomes of assisted reproductive technology (ART). During controlled ovarian stimulation, rising estradiol increases thyroxine-binding globulin and thyroid hormone requirements. These physiological changes, combined with increased metabolic demand in early pregnancy, may worsen SCH and contribute to adverse outcomes such as miscarriage, preterm birth, and hypertensive disorders of pregnancy.\n\nAlthough levothyroxine (LT4) is routinely used to treat overt hypothyroidism, evidence for its benefit in SCH, especially among infertile women undergoing In Vitro Fertilization (IVF) or Intra-Cytoplasmic Sperm Injection (ICSI) with frozen embryo transfer (FET), remains inconclusive. Some trials and meta-analyses have shown reductions in miscarriage and neonatal mortality, while others have found no improvement in ART or obstetric outcomes.\n\nThis study aims to evaluate the effectiveness of levothyroxine therapy on IVF\u002FFET outcomes and subsequent pregnancy results in women with subclinical hypothyroidism and infertility. This retrospective cohort study will emulate the target trial to evaluate whether LT4 treatment, titrated to achieve a pre-transfer TSH \\\u003C 2.5 mIU\u002FL, improves implantation, live birth, and obstetric outcomes compared with expectant management.",[30,88,89,90,91,92],"Infertility","Assisted Reproductive Technology","In Vitro Fertilization (IVF)","Intracytoplasmic Sperm Injection","Frozen Embryo Transfer (FET)",[27,30,88,94,95,96,97,98,89,99,100,101,102],"Thyroid Disorders","IVF","ICSI","Frozen Embryo Transfer","FET","Live Birth","Miscarriage","Pregnancy Outcomes","Thyroid Autoimmunity","2026-01-13",{"date":105,"type":35},"2026-01-14",{"date":107,"type":35},"2019-01-01",{"date":109,"type":21},"2026-03-30",{"name":111,"class":42},"Mỹ Đức Hospital",2,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":119,"sex":16,"minAge":81,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":43},"100611139","impact-of-subclinical-hypothyroidism-on-liver-enzymes-and-lipid-profile-100611139","NCT07236697","Impact of Subclinical Hypothyroidism on Liver Enzymes and Lipid Profile","Inclusion Criteria:\n\n* • Age ≥ 18 years\n\n  * For SCH group: Elevated TSH with normal FT4\n  * For control group: Normal TSH and FT4 levels\n\nExclusion Criteria:\n\n* • Evident hypothyroidism or hyperthyroidism\n\n  * Diagnosed with diabetes mellitus\n  * Chronic liver disease\n  * Chronic kidney disease\n  * Use of lipid-lowering or thyroid medications\n  * Pregnancy\n  * Alcohol abuse",true,"60 Years",{"count":122,"type":21},120,"the goal of the randomized controlled observational study is to observe the effect of subclinical hypothyroidism on liver enzymes and lipid profile",[30],[126],"subclinical hypothyroidism on liver enzymes and lipid profile","NOT_YET_RECRUITING","2025-11-15",{"date":130,"type":35},"2025-11-19",{"date":132,"type":21},"2025-12-01",{"date":134,"type":21},"2026-12-01",{"name":136,"class":42},"Assiut University",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":80,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":43},"100519258","best-treatment-for-women-with-both-polycystic-ovary-syndrome-pcos-and-subclinical-hypothyroidism-100519258","NCT06041204","Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism","Letrozole Alone vs. Letrozole Plus Levothyroxine for Ovulation Induction in Infertile Women With Both (Polycystic Ovary Syndrome) PCOS and Sub-clinical Hypothyroidism.","Inclusion Criteria:\n\nAge between 20-40 years\n\nBMI between 18-35 kg\u002Fm2\n\nMeet diagnostic criteria for PCOS based on the Rotterdam consensus criteria and ESHRE\u002FASRM modifications (2018):\n\nOligo- and\u002For anovulation Clinical and\u002For biochemical signs of hyperandrogenism Polycystic ovaries on ultrasound\n\nSubclinical hypothyroidism defined as TSH level between 5-10 mIU\u002FL with normal free T4\n\nInfertility duration ≥ 1 year\n\nIntact ovaries and uterus, confirmed by physical exam and imaging\n\nNormal semen analysis in male partner\n\nNo tubal or peritoneal factor contributing to infertility\n\nEffective contraception if not attempting conception\n\nWilling and able to provide informed consent\n\nExclusion Criteria:\n\nKnown thyroid disease or on thyroid medications\n\nAbnormal thyroid function tests other than subclinical hypothyroidism\n\nHyperprolactinemia\n\nPresence of other causes of infertility such as:\n\nModerate to severe male factor infertility Bilateral tubal occlusion or peritoneal factors Stage III-IV endometriosis Ovarian failure or insufficiency (high FSH or low AMH)\n\nPrevious diagnosis of any type of congenital adrenal hyperplasia\n\nUncontrolled diabetes (HbA1C \\>8%)\n\nHistory of deep vein thrombosis or thromboembolic events\n\nAny contraindication to letrozole or levothyroxine\n\nPrevious use of letrozole or levothyroxine in past 6 months\n\nCurrent or suspected pregnancy\n\nBreastfeeding\n\nInability to comply with treatment and follow-up procedures","20 Years","40 Years",{"count":147,"type":21},200,[24],"The goal of this randomized controlled trial is to compare letrozole alone versus letrozole plus levothyroxine for ovulation induction in infertile women with both PCOS and subclinical hypothyroidism. The main questions it aims to answer are:\n\nIs letrozole plus levothyroxine superior to letrozole alone in achieving ovulation in these patients? Does combining levothyroxine with letrozole lead to higher pregnancy and live birth rates compared to letrozole alone?\n\nParticipants will be randomized into two groups:\n\nGroup 1 will receive letrozole only, starting at 2.5 mg daily from day 3 to 7 of the menstrual cycle. The dose will be increased up to 7.5 mg if no ovulation occurs, for a maximum treatment period of 6 months or until pregnancy is achieved.\n\nGroup 2 will receive letrozole at the same doses as group 1 plus 25 mcg levothyroxine daily.",[151,30,152],"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries","Female Infertility",[154,27,155,156],"Letrozole","PCOS","Subclinical hypothyroidism","2025-08-30",{"date":159,"type":35},"2025-09-03",{"date":161,"type":35},"2021-05-06",{"date":163,"type":21},"2026-06-28",{"name":165,"class":42},"Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy"]